<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04527289</url>
  </required_header>
  <id_info>
    <org_study_id>Amantadine on TBI</org_study_id>
    <nct_id>NCT04527289</nct_id>
  </id_info>
  <brief_title>Impact of Amantadine on Traumatic Brain Injury</brief_title>
  <official_title>Potential Impact of Amantadine on Traumatic Brain Injury Outcomes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Damanhour University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Damanhour University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to evaluate whether the addition of amantadine to the management&#xD;
      regimen of traumatic brain injury patients would have a favorable effect on recovery and&#xD;
      neurological complications in association with prognosis biomarkers Interleukin-18 (IL-18),&#xD;
      Neuron-specific enolase (NSE) and (Neurotensin).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Proposal Steps&#xD;
&#xD;
        1. Approval will be obtained from Research Ethics Committee of Faculty of Pharmacy,&#xD;
           Damanhour University.&#xD;
&#xD;
        2. All participants agreed to take part in this clinical study and provide informed&#xD;
           consent.&#xD;
&#xD;
        3. Patients will be enrolled if they present with clinical signs of trauma, from Emergency&#xD;
           department at Tanta University Hospital&#xD;
&#xD;
        4. Complete physical, laboratory, radiological assessment will be done for all patients&#xD;
&#xD;
        5. Serum samples will be collected for measuring the biomarkers.&#xD;
&#xD;
        6. All enrolled 50 patients will be divided into two groups; Group I are patients who will&#xD;
           receive amantadine as added on therapy. Group II are patients who will be managed with&#xD;
           the standard regimen.&#xD;
&#xD;
        7. All patients will be followed up during 6 weeks period.&#xD;
&#xD;
        8. At the end of 6 weeks, prognosis biomarkers will be withdrawn.&#xD;
&#xD;
        9. Statistical tests appropriate to the study design will be conducted to evaluate the&#xD;
           significance of the results.&#xD;
&#xD;
       10. Measuring outcome: The primary outcome is to compare the effect of adding amantadine on&#xD;
           recovery rate and neurological complications in trauma patients.&#xD;
&#xD;
       11. Results, conclusion, discussion and recommendations will be given.&#xD;
&#xD;
      Methodology&#xD;
&#xD;
        -  50 Patients will be randomized equally to the assigned study groups&#xD;
&#xD;
        -  Prognosis biomarkers (IL-18, NSE and Neurotensin) will be measured using ELISA&#xD;
&#xD;
        -  Conventional routine tests (including renal function tests) will be assessed&#xD;
&#xD;
        -  Patients will be evaluated clinically (such as Glasgow score…) for recovery rate for&#xD;
           neurological complications.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 30, 2020</start_date>
  <completion_date type="Anticipated">October 5, 2021</completion_date>
  <primary_completion_date type="Actual">October 1, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>All enrolled 50 patients will be divided into two groups; Group I are patients who will receive amantadine as add on therapy. Group II are patients who will be managed with the standard regimen.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>double blind</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Neurotensin pg/ml</measure>
    <time_frame>6 weeks</time_frame>
    <description>Neurotensin pg/ml by ELISA Kit</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Neuron specific enolase (NSE) ng/mL</measure>
    <time_frame>6 Weeks</time_frame>
    <description>Neuron specific enolase (NSE) by ELISA Kit</description>
  </primary_outcome>
  <primary_outcome>
    <measure>interleukin-18 (IL-18) pg/ml</measure>
    <time_frame>6 Weeks</time_frame>
    <description>interleukin-18 (IL-18) by ELISA Kit</description>
  </primary_outcome>
  <primary_outcome>
    <measure>(GCS) Total Glasgow Coma Scale score: (Severe: GCS 8 or less- Moderate: GCS 9-12- Mild: GCS 13-15)</measure>
    <time_frame>6 weeks</time_frame>
    <description>noumber of GCS to describe the level of consciousness in a person following a traumatic brain injury.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>ICU stay (days)</measure>
    <time_frame>6 weeks</time_frame>
    <description>ICU stay (days)</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Trauma, Brain</condition>
  <arm_group>
    <arm_group_label>Amantadine Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group, I are patients who will receive amantadine (100mg) as add on therapy to the standard regimen.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Group II are patients who will be managed with the standard regimen.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amantadine (100mg) as add on therapy.</intervention_name>
    <description>Amantadine (100mg) as add on therapy to the management regimen of traumatic brain injury - 100mg twice daily Oral or feeding tube</description>
    <arm_group_label>Amantadine Group</arm_group_label>
    <other_name>PK-merz</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>patients will be managed with placebo as add on to the standard regimen.</description>
    <arm_group_label>Placebo Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -  Inclusion criteria&#xD;
&#xD;
             •Adult patients will be enrolled if they present with clinical signs of trauma brain&#xD;
             injury&#xD;
&#xD;
          -  Exclusion criteria&#xD;
&#xD;
               -  Age lower than 18&#xD;
&#xD;
               -  Females with positive pregnancy test&#xD;
&#xD;
               -  Known congestive heart failure or ischemic heart disease&#xD;
&#xD;
               -  Any injury disturbs the examination (high cervical cord injury or locked-in&#xD;
                  syndrome, could be a source of bias)&#xD;
&#xD;
               -  Penetrating head trauma&#xD;
&#xD;
               -  Need for any operation (laparotomy or craniotomy)&#xD;
&#xD;
               -  Severe brain disease (For example CVA history or brain tumour)&#xD;
&#xD;
               -  Renal failure with GFR lower than 60 ml/min&#xD;
&#xD;
               -  Patients with unknown identity&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rehab H Werida, Lecturer</last_name>
    <role>Study Director</role>
    <affiliation>Damanhour University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Rehab H Werida, Lecturer</last_name>
    <phone>+201005359968</phone>
    <email>rehabwrieda@pharm.dmu.edu.eg</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mennatullah G Elmalky, PharmD</last_name>
    <phone>0201010006215</phone>
    <email>Mennashahin1993@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Tanta University Hospital</name>
      <address>
        <city>Tanta</city>
        <state>Elgarbia</state>
        <zip>31527</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rehab H Werida, Lecturer</last_name>
      <phone>01005359968</phone>
      <email>rehabwrieda@pharm.dmu.edu.eg</email>
    </contact>
    <contact_backup>
      <last_name>Mohamed Shama, Lecturer</last_name>
      <email>m_shama80@yahoo.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <reference>
    <citation>Stelmaschuk S, Will MC, Meyers T. Amantadine to Treat Cognitive Dysfunction in Moderate to Severe Traumatic Brain Injury. J Trauma Nurs. 2015 Jul-Aug;22(4):194-203; quiz E1-2. doi: 10.1097/JTN.0000000000000138. Review.</citation>
    <PMID>26165872</PMID>
  </reference>
  <reference>
    <citation>Bharosay A, Bharosay VV, Varma M, Saxena K, Sodani A, Saxena R. Correlation of Brain Biomarker Neuron Specific Enolase (NSE) with Degree of Disability and Neurological Worsening in Cerebrovascular Stroke. Indian J Clin Biochem. 2012 Apr;27(2):186-90. doi: 10.1007/s12291-011-0172-9. Epub 2011 Nov 8.</citation>
    <PMID>23542317</PMID>
  </reference>
  <reference>
    <citation>Ciaramella A, Della Vedova C, Salani F, Viganotti M, D'Ippolito M, Caltagirone C, Formisano R, Sabatini U, Bossù P. Increased levels of serum IL-18 are associated with the long-term outcome of severe traumatic brain injury. Neuroimmunomodulation. 2014;21(1):8-12. doi: 10.1159/000354764. Epub 2013 Sep 26.</citation>
    <PMID>24080899</PMID>
  </reference>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>August 22, 2020</study_first_submitted>
  <study_first_submitted_qc>August 22, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 26, 2020</study_first_posted>
  <last_update_submitted>October 4, 2021</last_update_submitted>
  <last_update_submitted_qc>October 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Damanhour University</investigator_affiliation>
    <investigator_full_name>Rehab Werida</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>traumatic brain injury (TBI)</keyword>
  <keyword>Interleukin-18 (IL-18)</keyword>
  <keyword>Neuron specific enolase (NSE)</keyword>
  <keyword>Neurotensin (NT)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Brain Injuries</mesh_term>
    <mesh_term>Brain Injuries, Traumatic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amantadine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

